Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

• TD Cowen 44^th Annual Health Care Conference (Boston, Massachusetts)
  • Tuesday, March 5, 2024, at 10:30 a.m. ET, panel
• Leerink Partners Global Biopharma Conference (Miami, Florida)
  • Tuesday, March 12, 2024, at 10:40 a.m. ET, corporate presentation
• Barclays 26^th Annual Global Healthcare Conference (Miami, Florida)
  • Wednesday, March 13, 2024, at 2:05 p.m. ET, fireside chat
• Stifel 2024 CNS Days (Virtual)
  • Tuesday, March 19, 2024, at 11:30 a.m. ET, fireside chat

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California.

Alector Contacts:
Alector
Katie Hogan
202-549-0557
[email protected]

1AB (media)
Dan Budwick
973-271-6085
[email protected]

Argot Partners (investors)
Laura Perry
212-600-1902
[email protected]